ENDRA Life Sciences Inc. (NDRA) stock
NDRANasdaqElectromedical & Electrotherapeutic ApparatusFiscal year ends December 31
$4.04+0.12 (+2.93%)
Close on Nov 18, 2026Market cap $6.05MP/E –Yield –
ENDRA Life Sciences ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
ENDRA Life Sciences's ebitda for the twelve months ending Jun 30, 2026 was -$6.61M. For fiscal 2025 it was -$5.72M. The highest annual figure on record is -$1.73M in fiscal 2016.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$5.72M | – |
| FY2024 | Dec 31, 2024 | -$10.77M | – |
| FY2023 | Dec 31, 2023 | -$10.40M | – |
| FY2022 | Dec 31, 2022 | -$13.06M | – |
| FY2021 | Dec 31, 2021 | -$11.38M | – |
| FY2020 | Dec 31, 2020 | -$11.40M | – |
| FY2019 | Dec 31, 2019 | -$10.76M | – |
| FY2018 | Dec 31, 2018 | -$8.95M | – |
| FY2017 | Dec 31, 2017 | -$4.56M | – |
| FY2016 | Dec 31, 2016 | -$1.73M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$1.48M | – |
| Q1 FY2026 | Mar 31, 2026 | -$2.16M | – |
| Q4 FY2025 | Dec 31, 2025 | -$1.61M | – |
| Q3 FY2025 | Sep 30, 2025 | -$1.36M | – |
| Q2 FY2025 | Jun 30, 2025 | -$1.29M | – |
| Q1 FY2025 | Mar 31, 2025 | -$1.46M | – |
| Q4 FY2024 | Dec 31, 2024 | -$4.29M | – |
| Q3 FY2024 | Sep 30, 2024 | -$1.50M | – |
| Q2 FY2024 | Jun 30, 2024 | -$2.22M | – |
| Q1 FY2024 | Mar 31, 2024 | -$2.77M | – |
| Q4 FY2023 | Dec 31, 2023 | -$1.44M | – |
| Q3 FY2023 | Sep 30, 2023 | -$3.10M | – |
| Q2 FY2023 | Jun 30, 2023 | -$2.96M | – |
| Q1 FY2023 | Mar 31, 2023 | -$2.90M | – |
| Q4 FY2022 | Dec 31, 2022 | -$3.28M | – |
| Q3 FY2022 | Sep 30, 2022 | -$3.39M | – |
| Q2 FY2022 | Jun 30, 2022 | -$3.55M | – |
| Q1 FY2022 | Mar 31, 2022 | -$2.84M | – |
| Q4 FY2021 | Dec 31, 2021 | -$3.05M | – |
| Q3 FY2021 | Sep 30, 2021 | -$2.62M | – |
| Q2 FY2021 | Jun 30, 2021 | -$3.17M | – |
| Q1 FY2021 | Mar 31, 2021 | -$2.54M | – |
| Q4 FY2020 | Dec 31, 2020 | -$2.20M | – |
| Q3 FY2020 | Sep 30, 2020 | -$3.25M | – |
| Q2 FY2020 | Jun 30, 2020 | -$2.87M | – |
| Q1 FY2020 | Mar 31, 2020 | -$3.08M | – |
| Q4 FY2019 | Dec 31, 2019 | -$3.11M | – |
| Q3 FY2019 | Sep 30, 2019 | -$2.62M | – |
| Q2 FY2019 | Jun 30, 2019 | -$2.31M | – |
| Q1 FY2019 | Mar 31, 2019 | -$2.73M | – |
| Q4 FY2018 | Dec 31, 2018 | -$1.98M | – |
| Q3 FY2018 | Sep 30, 2018 | -$2.34M | – |
| Q2 FY2018 | Jun 30, 2018 | -$1.81M | – |
| Q1 FY2018 | Mar 31, 2018 | -$2.82M | – |
| Q4 FY2017 | Dec 31, 2017 | -$2.28M | – |
| Q3 FY2017 | Sep 30, 2017 | -$895.78K | – |
| Q2 FY2017 | Jun 30, 2017 | -$1.04M | – |
| Q1 FY2017 | Mar 31, 2017 | -$345.01K | – |
| Q4 FY2016 | Dec 31, 2016 | -$302.56K | – |
| Q3 FY2016 | Sep 30, 2016 | -$588.77K | – |
See a number that looks wrong?